

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. PB60432	SERIAL NO. 10/567,803
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Coles, et al.	
		FILING DATE March 31, 2008	GROUP 1615

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

/D.A./	Bristol-Myers Squibb Company. Glucophage® (metformin hydrochloride tablets) and Glucophage® XR (metformin hydrochloride extended release tablets). NDA 20-357/S-031 and NDA 21-202/S-016. Pages 3-32.

EXAMINER

/Danah Al-awadi/

DATE CONSIDERED

08/16/2010

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copyof this form with next communication to applicant.